Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$103.45 USD
-0.23 (-0.22%)
Updated Jun 17, 2024 04:00 PM ET
After-Market: $104.00 +0.55 (0.53%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth C Momentum C VGM
Brokerage Reports
Abbott Laboratories [ABT]
Reports for Purchase
Showing records 381 - 400 ( 528 total )
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Niche stents and aggressive business initiatives - measures to drive overall performance
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Strengthening U.S. Dollar to be a major headwind in 2015, with 70% of total sales coming from outside the U.S
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Strengthening U.S. Dollar to be a major headwind in 2015, as 70% of ABT?s sales comes from
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Strengthening U.S. Dollar to be a major headwind in 2015, as 70% of ABT?s sales comes from
Provider: FIRST GLOBAL
Analyst: THOMAS K